- English (UK)
- English (India)
- English (Canada)
- English (Australia)
- English (South Africa)
- English (Philippines)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Legend Biotech Corp (LEGN)
Legend Biotech Corp stock price live, this page displays NASDAQ LEGN stock exchange data. View the LEGN premarket stock price ahead of the market session or assess the after hours quote. Monitor the latest movements within the Legend Biotech Corp real time stock price chart below.
What Is the Legend Biotech Corp Stock Price Today?
The Legend Biotech Corp stock price today is 21.92.
What Is the Stock Symbol for Legend Biotech Corp?
The stock ticker symbol for Legend Biotech Corp is LEGN.
Is LEGN the Same as $LEGN?
$LEGN is a common way to refer to the Legend Biotech Corp ticker symbol in social media, forums, and online discussions. The dollar sign is a shorthand convention used to indicate that it is a stock ticker symbol
What Stock Exchange Does Legend Biotech Corp Trade On?
Legend Biotech Corp is listed and trades on the NASDAQ stock exchange.
Is Legend Biotech Corp a Good Stock to Buy?
Determining whether Legend Biotech Corp—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess the current Legend Biotech Corp share price compared with the fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the LEGN quote. (ISIN: US52490G1022)
What Is the Legend Biotech Corp Stock Price Today?
The Legend Biotech Corp stock price today is 21.92.
What Is the Stock Symbol for Legend Biotech Corp?
The stock ticker symbol for Legend Biotech Corp is LEGN.
Is LEGN the Same as $LEGN?
$LEGN is a common way to refer to the Legend Biotech Corp ticker symbol in social media, forums, and online discussions. The dollar sign is a shorthand convention used to indicate that it is a stock ticker symbol
What Stock Exchange Does Legend Biotech Corp Trade On?
Legend Biotech Corp is listed and trades on the NASDAQ stock exchange.
Is Legend Biotech Corp a Good Stock to Buy?
Determining whether Legend Biotech Corp—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess the current Legend Biotech Corp share price compared with the fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the LEGN quote. (ISIN: US52490G1022)
21.92
+0.66(+3.10%)
Real-time Data·
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
21.38
22.37
52 wk Range
16.24
37.50
LEGN is not included in our AI-picked strategies. See which stocks are.
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
21.3822.37
52 wk Range
16.2437.50
Key Statistics
Edit
Prev. Close
Open
Volume
Average Vol. (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Vol. (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
LEGN Scorecard
Company’s Health
Assesses a company's financial position by analyzing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PricePrice Target
49.25
Upside
+124.67%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
Liquid assets exceed short term obligations
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Neutral
Technical Indicators
Sell
Moving Averages
Buy
Analyst Ratings
10 Buy
5 Hold
0 Sell
Ratings:
15 analysts
Overall Consensus
Buy
Analysts 12-Month Price Target:
Average 49.25
(+124.67% Upside)
Legend Biotech Corp SWOT Analysis
Financial Trajectory | Analyst targets range from $66 to $94, with profitability expected by Q2 2026. Learn how Carvykti's success and pipeline advancements could drive Legend's valuation |
Pipeline Potential | Uncover Legend's diverse pipeline beyond Carvykti, including promising early-stage candidates in gastric, esophageal, and lung cancers, offering multiple growth avenues |
Manufacturing Mastery | Delve into Legend's strategic expansion of manufacturing capacity, aiming to meet growing patient demand and overcome supply chain challenges by year-end 2025 |
Carvykti's Triumph | Explore Legend Biotech's market dominance with Carvykti, a groundbreaking multiple myeloma therapy showing impressive clinical results and strong commercial performance |
Legend Biotech Corp Earnings Call Summary for Q2/2026
- Legend Biotech posted Q2 adjusted EPS of $0.16 vs. $0.07 est., revenue of $387.5M vs. $362.8M est.; first profitable quarter company-wide.
- CARVYKTI sales rose 50% YoY to ~$657M; U.S. sales up 32%, ex-U.S. up 128%; operating margin improved to 15% from negative 9% YoY.
- Management expects adjusted net income profitability through H2 2026; gross margin to reach mid-50% in Q4, targeting 75% long-term.
- Company plans U.S. IND filing for LB2501 in vivo CAR-T by end-2026; CEO search ongoing after leadership transition from Ying Huang.
- Shares rose 5% premarket to $21.70; company holds $965M cash with no long-term debt, plans to settle ~$300M J&J loan in 2026.
Last Updated: 08/11/2026, 08:58 AM
Read Full TranscriptLegend Bio investor slides for Q2/2026
Last Update: Aug 11, 2026
See full investor slides
Earnings
Latest Release
Aug 11, 2026
EPS / Forecast
0.16 / 0.07
Revenue / Forecast
387.5M / 362.81M
Compare LEGN to Peers and Sector
Metrics to compare | LEGN | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipLEGNPeersSector | |
|---|---|---|---|---|
P/E Ratio | −46.7x | −2.7x | −0.3x | |
PEG Ratio | −0.63 | −0.05 | 0.00 | |
Price / Book | 3.5x | 3.6x | 2.6x | |
Price / LTM Sales | 3.4x | 79.4x | 3.1x | |
Upside (Analyst Target) | 130.5% | 261.3% | 47.6% | |
Fair Value Upside | Unlock | 2.1% | 5.6% | Unlock |
Legend Biotech Corporation, through its subsidiaries, operates as a biopharmaceutical company that discovers, develops, manufactures, and commercializes novel cell therapies for oncology and other indications in the United States, China, and Europe. Its lead product candidate is ciltacabtagene autoleucel, or cilta-cel, which is a chimeric antigen receptor (CAR-T) therapy for the treatment of multiple myeloma (MM). The company also has a portfolio of earlier-stage autologous CAR-T product candidates targeting various cancers, including acute lymphoblastic leukemia, gastric cancer, esophageal cancer, pancreatic cancer, colorectal cancer, small cell lung cancer, and non-small cell lung cancer. In addition, it develops allogeneic gamma delta CAR-T and allogeneic CAR-NK product candidates targeting B-cell maturation antigen (BCMA) for MM, which are in investigator-initiated Phase 1 clinical trials in China. The company has a collaboration and license agreement with Janssen Biotech, Inc. for the development and commercialization of cilta-cel, as well as a license agreement with Novartis Pharma AG for the development, manufacture, and commercialization of CAR-T cell therapies targeting delta-like ligand protein 3. Legend Biotech Corporation was founded in 2014 and is headquartered in Somerset, New Jersey.
Ownership
Ownership Overview
Top Holders
People Also Watch
FAQ
What Is the Legend Bio (LEGN) Stock Price Today?
The Legend Bio stock price today is 21.92 USD.
What Stock Exchange Does Legend Bio Trade On?
Legend Bio is listed and trades on the Nasdaq Stock Exchange.
What Is the Stock Symbol for Legend Bio?
The stock symbol for Legend Bio is "LEGN."
What Is the Legend Bio Market Cap?
As of today, Legend Bio market cap is 4.25B USD.
What Is Legend Bio's Earnings Per Share (TTM)?
The Legend Bio EPS (TTM) is -0.50.
When Is the Next Legend Bio Earnings Date?
Legend Bio will release its next earnings report on Nov 17, 2026.
From a Technical Analysis Perspective, Is LEGN a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Buy.
How Many Times Has Legend Bio Stock Split?
Legend Bio has split 0 times.
How Many Employees Does Legend Bio Have?
Legend Bio has 3200 employees.
What is the current trading status of Legend Bio (LEGN)?
As of Aug 21, 2026, Legend Bio (LEGN) is trading at a price of 21.92 USD, with a previous close of 21.26 USD. The stock has fluctuated within a day range of 21.38 USD to 22.37 USD, while its 52-week range spans from 16.24 USD to 37.50 USD.
What Is Legend Bio (LEGN) Price Target According to Analysts?
The average 12-month price target for Legend Bio is 49.25 USD, with a high estimate of 78 USD and a low estimate of 24 USD. 10 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Buy. The stock has an +124.67% Upside potential.
What Is the LEGN Premarket Price?
LEGN's last pre-market stock price is 21.49 USD. The pre-market share volume is 7,070.00, and the stock has decreased by 0.23, or 1.08%.
What Is the LEGN After Hours Price?
LEGN's last after hours stock price is 21.53 USD, the stock has decreased by 0.27, or 1.27%.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.